The Incidence of Treatment-Requiring Retinopathy of Prematurity in Greece: A Multicenter Prospective Cohort Study.

IF 1.7 4区医学 Q3 OPHTHALMOLOGY

Ophthalmic epidemiology Pub Date : 2025-03-10 DOI:10.1080/09286586.2025.2463069

Asimina Mataftsi, Stella Moutzouri, Alexandros Charonis, Aikaterini K Seliniotaki, Anna-Bettina Haidich, Nikolaos Ziakas

{"title":"The Incidence of Treatment-Requiring Retinopathy of Prematurity in Greece: A Multicenter Prospective Cohort Study.","authors":"Asimina Mataftsi, Stella Moutzouri, Alexandros Charonis, Aikaterini K Seliniotaki, Anna-Bettina Haidich, Nikolaos Ziakas","doi":"10.1080/09286586.2025.2463069","DOIUrl":null,"url":null,"abstract":"Purpose: To report the incidence of treatment-requiring retinopathy of prematurity (ROP) in Greece at a national level.Methods: Multicenter prospective cohort study of infants that required treatment for ROP at any unit in Greece between June 1st, 2020, and May 31st, 2021. Twelve out of the 13 invited centers contributed their data. Collected parameters included infants' demographics, ROP examination findings prior to treatment, and treatment characteristics.Results: The overall incidence of treatment-requiring ROP (TR-ROP) was 3.8%, given the fact that 1133 live births of infants with GA <32 weeks and/or BW < 1501 g were reported during the study period. Median (range) gestational age and birth weight of treated infants were 26.9 (23.4-33.0) weeks and 850 (500-2370) g, respectively, and 55.8% were male. The most prevalent ROP severity among treated infants was type 1 ROP (70 eyes), followed by type 2 ROP (8 eyes) and aggressive ROP (6 eyes). Laser photocoagulation (69.8%) was the predominant treatment modality used vs intravitreal anti-VEGF injections (30.2%). The median postnatal age at initial treatment was 9.6 weeks (range 5.6-21.7). Re-treatment rate was 30.2% and was higher among infants treated with anti-VEGF (69.2%) vs laser (13.3%). Treatment failure was reported in one case (progression to stage 4B in one eye and stage 5 in the other), whereas ROP regressed in all other patients.Conclusion: This is the first study to report TR-ROP incidence in Greece, treated infants' characteristics at a national level, preferred practice patterns, failure rate and recurrence rate at 6 months from initial treatment.","PeriodicalId":19607,"journal":{"name":"Ophthalmic epidemiology","volume":" ","pages":"1-7"},"PeriodicalIF":1.7000,"publicationDate":"2025-03-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Ophthalmic epidemiology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1080/09286586.2025.2463069","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"OPHTHALMOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Purpose: To report the incidence of treatment-requiring retinopathy of prematurity (ROP) in Greece at a national level.

Methods: Multicenter prospective cohort study of infants that required treatment for ROP at any unit in Greece between June 1^st, 2020, and May 31^st, 2021. Twelve out of the 13 invited centers contributed their data. Collected parameters included infants' demographics, ROP examination findings prior to treatment, and treatment characteristics.

Results: The overall incidence of treatment-requiring ROP (TR-ROP) was 3.8%, given the fact that 1133 live births of infants with GA <32 weeks and/or BW < 1501 g were reported during the study period. Median (range) gestational age and birth weight of treated infants were 26.9 (23.4-33.0) weeks and 850 (500-2370) g, respectively, and 55.8% were male. The most prevalent ROP severity among treated infants was type 1 ROP (70 eyes), followed by type 2 ROP (8 eyes) and aggressive ROP (6 eyes). Laser photocoagulation (69.8%) was the predominant treatment modality used vs intravitreal anti-VEGF injections (30.2%). The median postnatal age at initial treatment was 9.6 weeks (range 5.6-21.7). Re-treatment rate was 30.2% and was higher among infants treated with anti-VEGF (69.2%) vs laser (13.3%). Treatment failure was reported in one case (progression to stage 4B in one eye and stage 5 in the other), whereas ROP regressed in all other patients.

Conclusion: This is the first study to report TR-ROP incidence in Greece, treated infants' characteristics at a national level, preferred practice patterns, failure rate and recurrence rate at 6 months from initial treatment.

查看原文本刊更多论文

希腊早产儿需要治疗的视网膜病变发生率：一项多中心前瞻性队列研究

目的：在希腊国家层面报道需要治疗的早产儿视网膜病变（ROP）的发病率。方法：对2020年6月1日至2021年5月31日期间在希腊任何单位需要治疗ROP的婴儿进行多中心前瞻性队列研究。13个受邀中心中有12个提供了他们的数据。收集的参数包括婴儿人口统计学、治疗前ROP检查结果和治疗特征。结果：考虑到1133例GA患儿的活产，需要治疗的ROP （TR-ROP）的总发生率为3.8%。结论：这是首个在希腊报告TR-ROP发病率的研究，在全国范围内报告了治疗婴儿的特征、首选实践模式、失败率和初始治疗后6个月的复发率。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Ophthalmic epidemiology 医学-眼科学

CiteScore

3.70

自引率

5.60%

发文量

审稿时长

6-12 weeks

期刊介绍： Ophthalmic Epidemiology is dedicated to the publication of original research into eye and vision health in the fields of epidemiology, public health and the prevention of blindness. Ophthalmic Epidemiology publishes editorials, original research reports, systematic reviews and meta-analysis articles, brief communications and letters to the editor on all subjects related to ophthalmic epidemiology. A broad range of topics is suitable, such as: evaluating the risk of ocular diseases, general and specific study designs, screening program implementation and evaluation, eye health care access, delivery and outcomes, therapeutic efficacy or effectiveness, disease prognosis and quality of life, cost-benefit analysis, biostatistical theory and risk factor analysis. We are looking to expand our engagement with reports of international interest, including those regarding problems affecting developing countries, although reports from all over the world potentially are suitable. Clinical case reports, small case series (not enough for a cohort analysis) articles and animal research reports are not appropriate for this journal.